Fuse lit to new range of diagnostic tests
Flip Mycoplasma, the first product in the new range, is described as a breakthrough test that delivers laboratory PCR quality results in just 12 minutes, enabling ultra-rapid detection of Mycoplasma contamination in cell cultures.
Designed to help eliminate reproducibility and quality issues in cell biology research and bioprocessing, it is said to empower end users to take immediate action – saving valuable time and reducing costs.
Fuse is developing a range of other Flip tests that address critical needs for rapid onsite testing within the industrial, food, water and veterinary sectors, including tests for Legionella and Avian Influenza.
Flip tests are provided in a ready-to-use format and exhibit exceptional diagnostic performance giving a clear visual result read-out in just minutes without any complex equipment or processing.
Fuse CEO Dr Harry Lamble said: “Flip is a transformative solution for rapid onsite testing that brings gold standard laboratory performance into a small, low-cost, disposable device format that anyone can use. We look forward to complementing Flip Mycoplasma with a range of other tests that allow users to overcome the delay and complexity of existing centralised instrument-based testing.”
Fuse raised £1.6 million in an oversubscribed seed investment round last year plus a separate $1m award from CARB-X, to develop its diagnostic testing platforms. In addition to the Flip product range, Fuse is investing in developing Apex, a fully integrated instrument-free test for point-of-care clinical diagnostic applications such as respiratory and sexually transmitted infections.
Fuse Diagnostics is focused on delivering laboratory-quality diagnostic information wherever it is needed through innovative, rapid, low-cost tests – addressing the cost and performance challenges of established approaches.
The company is developing a revolutionary new generation of multianalytic diagnostic products, based on its Flip and Apex platforms, to make accurate point-of-need testing a reality for all. Fuse founders Harry and Ralph Lamble previously founded Sense Biodetection where they developed the world’s first rapid instrument-free, molecular diagnostic test (Veros COVID-19) during the pandemic.
Following the acquisition of Sense by Sherlock Biosciences in 2023, the brothers decided to apply their experience of clinical product development and commercialisation to address the widespread demand for rapid onsite pathogen testing across industry.